Component
Caspase-3 activation in human myeloma-cell combinations
Caspase-3 activation in human myeloma-cell combinations. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The combination treatments increased caspase-3 activation in the myeloma-cell experiments.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/mangiferin-research/27035859.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "018c08f93a5101b1a7fbafdbc99357f6d4baa9eed19711ff63e6c7cd3d3ec13e", "start_char": 0, "end_char": 1327, "text_sha256": "018c08f93a5101b1a7fbafdbc99357f6d4baa9eed19711ff63e6c7cd3d3ec13e"}
- experimental_model
- Anticancer drug-combination experiments in myeloma cell lines
- exposure
- Mangiferin plus conventional anticancer agents; individual regimen not assigned from abstract
- limitations
- Cell viability and apoptosis findings do not establish clinical combination safety, benefit or formal pharmacologic synergy.
- nutrient_topic
- Mangiferin research collection; topical membership is not evidence of a direct dietary effect. · Mangiferin
- organism
- Homo sapiens
- plain_language
- Apoptosis machinery accompanied the viability response.
- primary_references
- [mangiferin-p27035859] Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway. (2016). https://pubmed.ncbi.nlm.nih.gov/27035859/ DOI: 10.3892/ijo.2016.3470
- tissue_or_cell_type
- Multiple-myeloma cell lines
Mangiferin: metabolism, signaling and nutrient connections (2026-09-17) · lines 1368–1379
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Anticancer drug-combination experiments in myeloma cell lines · source_derived_draft · unverified_draft
### mangiferin-myeloma-caspase The combination treatments increased caspase-3 activation in the myeloma-cell experiments. Condition category: normal nutrient_topic: Mangiferin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Apoptosis machinery accompanied the viability response. organism: Homo sapiens tissue_or_cell_type: Multiple-myeloma cell lines experimental_model: Anticancer drug-combination experiments in myeloma cell lines limitations: Cell viability and apoptosis findings do not establish clinical combination safety, benefit or formal pharmacologic synergy. exposure: Mangiferin plus conventional anticancer agents; individual regimen not assigned from abstract evidence_span: {"source_cache": "artifacts/mangiferin-research/27035859.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "018c08f93a5101b1a7fbafdbc99357f6d4baa9eed19711ff63e6c7cd3d3ec13e", "start_char": 0, "end_char": 1327, "text_sha256": "018c08f93a5101b1a7fbafdbc99357f6d4baa9eed19711ff63e6c7cd3d3ec13e"} [mangiferin-p27035859] Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway. (2016). https://pubmed.ncbi.nlm.nih.gov/27035859/ DOI: 10.3892/ijo.2016.3470
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.